[
  {
    "ts": null,
    "headline": "All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy",
    "summary": "Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
    "url": "https://finnhub.io/api/news?id=87be87379067008351aaf7449e0d6380e684f7e88387d87d381393f75120d2cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734627610,
      "headline": "All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy",
      "id": 132058533,
      "image": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
      "url": "https://finnhub.io/api/news?id=87be87379067008351aaf7449e0d6380e684f7e88387d87d381393f75120d2cf"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
    "summary": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d9aed710293af385aaff1a4ad885089d1c3d39d21e0ef66fff39659dfa25ff44",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626400,
      "headline": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
      "id": 132067211,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d9aed710293af385aaff1a4ad885089d1c3d39d21e0ef66fff39659dfa25ff44"
    }
  },
  {
    "ts": null,
    "headline": "Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?",
    "summary": "Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=1fd4175c04e87249f8201d1bafdf45510669035808b5f7aa170c528605dca1b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734619213,
      "headline": "Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?",
      "id": 132058534,
      "image": "https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=1fd4175c04e87249f8201d1bafdf45510669035808b5f7aa170c528605dca1b6"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific price target raised to $110 from $100 at Truist",
    "summary": "Truist raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance",
    "url": "https://finnhub.io/api/news?id=0bcee2bbf7a4a516139896c7a2eb8d2d28ababaf3f9d768e69775ace497b56aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734611456,
      "headline": "Boston Scientific price target raised to $110 from $100 at Truist",
      "id": 132050331,
      "image": "",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Truist raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance",
      "url": "https://finnhub.io/api/news?id=0bcee2bbf7a4a516139896c7a2eb8d2d28ababaf3f9d768e69775ace497b56aa"
    }
  },
  {
    "ts": null,
    "headline": "Should You Retain Henry Schein Stock in Your Portfolio Right Now?",
    "summary": "Investors are optimistic about HSIC owing to the performance of its dental business.",
    "url": "https://finnhub.io/api/news?id=4bbb063f35b4f9dd51802718a0c74a63b0ecea3d61d4ed89ceb62a743ee2c904",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734611040,
      "headline": "Should You Retain Henry Schein Stock in Your Portfolio Right Now?",
      "id": 132051756,
      "image": "https://media.zenfs.com/en/zacks.com/cd9fa2ca3125c2741152b27cc2930bff",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Investors are optimistic about HSIC owing to the performance of its dental business.",
      "url": "https://finnhub.io/api/news?id=4bbb063f35b4f9dd51802718a0c74a63b0ecea3d61d4ed89ceb62a743ee2c904"
    }
  },
  {
    "ts": null,
    "headline": "Impax Global Opportunities Fund Q3 2024 Commentary",
    "summary": "The Global Opportunities Fund outperformed its benchmark in the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=489f8a8d0be4cc8799e506a8cd262176e2ebeb9936482a87f98824308f7a526b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734604200,
      "headline": "Impax Global Opportunities Fund Q3 2024 Commentary",
      "id": 132052294,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170698203/image_2170698203.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "The Global Opportunities Fund outperformed its benchmark in the third quarter of 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=489f8a8d0be4cc8799e506a8cd262176e2ebeb9936482a87f98824308f7a526b"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific updates cryoablation catheter instructions after 4 death reports",
    "summary": "The update followed a higher than expected number of reports of esophageal injury after catheter ablation procedures for atrial fibrillation.",
    "url": "https://finnhub.io/api/news?id=94c96f4a1be22647bb4d7745b02479a7d7adb316bef1abdd08fc53b3283361aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734602160,
      "headline": "Boston Scientific updates cryoablation catheter instructions after 4 death reports",
      "id": 132058539,
      "image": "https://imgproxy.divecdn.com/80_eRk-7Lf80XDq2Q9e_JyhHdx4CfdjNlu0ZMkOOXzc/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HbG9iYWxfSGVhZHF1YXJ0ZXJzX01hcmxib3JvdWdoX01hc3MuanBn.webp",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The update followed a higher than expected number of reports of esophageal injury after catheter ablation procedures for atrial fibrillation.",
      "url": "https://finnhub.io/api/news?id=94c96f4a1be22647bb4d7745b02479a7d7adb316bef1abdd08fc53b3283361aa"
    }
  },
  {
    "ts": null,
    "headline": "The Gabelli ABC Fund Q3 2024  Commentary",
    "summary": "The Gabelli ABC Fund (class I) returned 3.45% for the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=ffa17ade7125b45a7f657ed38cd5cf1ed1a2bf2ca1c5baa53439a277e55afbd0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734587100,
      "headline": "The Gabelli ABC Fund Q3 2024  Commentary",
      "id": 132048588,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1719733826/image_1719733826.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "The Gabelli ABC Fund (class I) returned 3.45% for the third quarter of 2024. Click here to read the full commentary. \n",
      "url": "https://finnhub.io/api/news?id=ffa17ade7125b45a7f657ed38cd5cf1ed1a2bf2ca1c5baa53439a277e55afbd0"
    }
  }
]